



UNIVERSITY OF HELSINKI



<https://helda.helsinki.fi>

Helda

Prognostic value of near-infrared spectroscopy regional oxygen saturation and cerebrovascular reactivity index in acute traumatic neural injury: a Canadian High-Resolution Traumatic Brain Injury (CAHR-TBI) Cohort Study

Gomez, Alwyn

2024-03-14

Critical Care. 2024 Mar 14;28(1):78

<https://doi.org/10.1186/s13054-024-04859-6>

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.













Please cite the original version.

RESEARCH

Open Access



Prognostic value of near-infrared spectroscopy regional oxygen saturation and cerebrovascular reactivity index in acute traumatic neural injury: a Canadian High-Resolution Traumatic Brain Injury (CAHR-TBI) Cohort Study

Alwyn Gomez^{1,2*} , Logan Froese³ , Donald Griesdale⁴ , Eric P. Thelin^{5,6} , Rahul Raj⁷ ,
Levi van Iperenburg^{8,9} , Jeanette Tas^{8,9} , Marcel Aries^{8,9} , Kevin Y. Stein³ , Clare Gallagher^{10,11,12},
Francis Bernard¹³ , Andreas H. Kramer^{11,12,14}  and Frederick A. Zeiler^{15,16,2,3,5} 

Abstract

Background Near-infrared spectroscopy regional cerebral oxygen saturation (rSO₂) has gained interest as a raw parameter and as a basis for measuring cerebrovascular reactivity (CVR) due to its noninvasive nature and high spatial resolution. However, the prognostic utility of these parameters has not yet been determined. This study aimed to identify threshold values of rSO₂ and rSO₂-based CVR at which outcomes worsened following traumatic brain injury (TBI).

Methods A retrospective multi-institutional cohort study was performed. The cohort included TBI patients treated in four adult intensive care units (ICU). The cerebral oxygen indices, COx (using rSO₂ and cerebral perfusion pressure) as well as COx_a (using rSO₂ and arterial blood pressure) were calculated for each patient. Grand mean thresholds along with exposure-based thresholds were determined utilizing sequential chi-squared analysis and univariate logistic regression, respectively.

Results In the cohort of 129 patients, there was no identifiable threshold for raw rSO₂ at which outcomes were found to worsen. For both COx and COx_a, an optimal grand mean threshold value of 0.2 was identified for both survival and favorable outcomes, while percent time above – 0.05 was uniformly found to have the best discriminative value.

Conclusions In this multi-institutional cohort study, raw rSO₂ was found to contain no significant prognostic information. However, rSO₂-based indices of CVR, COx and COx_a, were found to have a uniform grand mean threshold of 0.2 and exposure-based threshold of – 0.05, above which clinical outcomes markedly worsened. This study lays the groundwork to transition to less invasive means of continuously measuring CVR.

Keywords Cerebrovascular reactivity, Multimodal monitoring, Near-infrared spectroscopy, Traumatic brain injury

*Correspondence:

Alwyn Gomez

gomeza35@myumanitoba.ca

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Contemporary critical care management of moderate-to-severe traumatic brain injury (TBI) remains focused on guideline-based universal intracranial pressure (ICP) and cerebral perfusion pressure (CPP) targets [1, 2]. Despite various iterations, outcomes in these critically ill patients have failed to improve over the past decades [3]. As a result, attention is shifting toward a multimodal monitoring approach in hopes of better understanding individual patient-level cerebral pathophysiologic states [4]. However, prior to driving management strategies, a thorough understanding of outcome associations of these various parameters must be developed.

One such modality of interest is near-infrared spectroscopy (NIRS). Near-infrared light has the ability to penetrate past the scalp and skull down to the cerebral parenchyma where it is scattered or absorbed by various chromophores depending on the wavelength of light emitted [5, 6]. In spatially resolved NIRS devices, light scattered from oxyhemoglobin and deoxyhemoglobin within the cerebral microvasculature can be detected, isolated, and utilized to calculate parameters such as regional cerebral oxygen saturation (rSO₂).

While advantageous due to its noninvasive nature and relatively high spatial resolution, the association of NIRS parameters and outcomes following TBI remains unclear [7]. There is a substantive body of the literature supporting an association between NIRS parameters and cerebral blood flow (CBF) but threshold values at which outcomes worsen have not been identified [8].

On the other hand, dysfunctional cerebral autoregulation/cerebrovascular reactivity (CVR) as a contributor to secondary injury following TBI has been greatly explored [9–12]. This has been largely facilitated by the development of continuous measures of CVR, the most prominent of which being the pressure reactivity index (PRx). PRx leverages ICP monitoring, typically indicated in the setting of moderate and severe TBI, as a surrogate for pulsatile cerebral blood volume (CBV) and arterial blood pressure (ABP) as a surrogate for driving pressure. Values closer to -1 are indicative of a vasoactive state (i.e., intact CVR), and values closer to $+1$ are indicative of a vasopassive state (i.e., disrupted CVR) [13].

A large body of evidence has validated the relationship between dysfunctional CVR, as measured by PRx, and poor functional outcomes following moderate-to-severe TBI [14–22]. Further, specific thresholds of PRx have been identified at which outcomes tend to worsen and mortality increases following TBI [22–24]. This has ultimately led to studies trying to therapeutically maintain PRx below critical thresholds [25–29].

For all its strengths, PRx does have its inherent limitations. Foremost, its reliance on invasive ICP

monitoring limits its application to settings where ICP monitoring is indicated. Thus, the use of PRx beyond the acute phase, or in milder TBIs, is limited. Additionally, ICP can only act as a global surrogate for CBV and therefore the spatial resolution of PRx is minimal with essentially only whole brain assessment being feasible. As a result, alternative means of evaluating local CVR continuously at the bedside have become of interest.

While NIRS-based parameters have had mixed evidence surrounding their utility in TBI care, leveraging these parameters to calculate metrics of CVR holds promise. In fact, NIRS-based indices of CVR are the only other continuous indices outside of ICP-based indices that have been shown to identify the lower limit of autoregulation in large animal models [30–32]. However, threshold values, at which clinical outcomes worsen, have not been identified.

This study explores the outcome associations of rSO₂, both as a raw NIRS parameter and as a surrogate for CBV in NIRS-based indices of CVR, with outcomes. It leverages the largest multicenter high-frequency physiologic data set with NIRS concurrently recorded with ICP and ABP in moderate-to-severe TBI, from the Canadian High-Resolution TBI (CAHR-TBI) Research Collaborative. The primary aim of this study was to identify the associations between these parameters and clinical outcomes following moderate-to-severe TBI. The secondary aim of this study was to identify threshold values for these parameters at which clinical outcomes worsen.

Methods

Study design

A retrospective multicenter cohort study was performed leveraging prospectively collected high-resolution physiologic data and clinical outcome data from the CAHR-TBI Research Collaborative [33]. The CAHR-TBI Research Collaborative is a multi-institutional collaboration pooling high-resolution physiologic data recordings from TBI patients admitted for moderate-to-severe TBI. The associated database contains physiologic data recordings dating back to 2011 and has prospective data collection ongoing. Local ethics approval for all aspects of data collection and anonymous data transfer between centers was obtained from the individual local research ethics boards: University of Manitoba Biomedical Research Ethics Board (BREB, H2017:181, H2017:188, H2020:118, B2023:001), University of Calgary Conjoint Health Research Ethics Board (CHREB, H20-03759), University of British Columbia Clinical Research Ethics Board (CREB, REB20-0482) and University of Maastricht Medical Ethics Committee (16-4-243).

Patient population

The CAHR-TBI database includes high-resolution physiologic data collected from moderate-to-severe TBI patients, defined as admission Glasgow Coma Scale (GCS) of less than 13, admitted to adult intensive care units (ICU) at participating institutions [33]. For the purposes of this retrospective study, data were collected at four university-affiliated hospitals: Foothills Medical Centre (University of Calgary), Health Sciences Centre Winnipeg (University of Manitoba), Maastricht University Medical Center (University of Maastricht), and Vancouver General Hospital (University of British Columbia). Patient demographics (age and biologic sex), admission injury severity characteristics (GCS and pupil reactivity), and imaging characteristics (Marshall CT score) were all collected. Finally, 6-month outcome data were also collected using the Extended Glasgow Outcome Scale (GOSE). Data regarding withdrawal of care were not available; however, as per local treatment guideline at each center, if care was decided to be withdrawn after the appropriate discussion with family/proxy, monitoring was discontinued. As such, physiologic data were only obtained during periods of active treatment. Given the exploratory and retrospective nature of this study, sample size calculations were not able to be performed and all datasets that met inclusion criteria were utilized for analysis.

Subjects from the CAHR-TBI database were included in this study if they had ICP, ABP, and rSO₂ monitoring. Recording was initiated within 24 h of time from injury. All patients received standard care based on published guidelines [1]. This included placement of ICP monitors, when indicated, and therapeutic treatment of ICP values greater than 20–22mmHg. A CPP target of greater than 60mmHg was also utilized. Notably, elevated CPP (>70mmHg) was not routinely treated as per local practice. While NIRS-based rSO₂ was collected on all included patients, it was not routinely utilized to guide clinical care. Finally, individual patient care was not guided by continuous CVR metrics.

High-resolution physiologic data collection

ICP was monitored utilizing an intraparenchymal probe (Codman ICP MicroSensor, Codman & Shurtleff Inc., Raynham, MA, USA; or NEUROVENT-P-TEMP, Raumedic Inc., Hambrecht, Germany; or Comino ICP monitor, Natus Medical Inc., Middleton, WI, USA) placed in the frontal lobe or with an external ventricular drain (EVD; Medtronic, Minneapolis, MN). No correction was made for monitor drift. ABP was obtained using a radial arterial line connected to a pressure transducer (Baxter Healthcare Corp. CardioVascular

Group, Irvine, CA, USA) zeroed at the level of the tragus. rSO₂ was collected using NIRS regional cerebral oximetry of both the left and right frontal lobes (INVOS 5100C or 7100, Covidien-Medtronic, Minneapolis, MN), where possible.

Data streams were recorded in digital high-frequency time series (≥ 100 Hz for ABP and ICP, oversampled at 1Hz for rSO₂, while signal generation was 0.2Hz) using analogue-to-digital signal converters (Data Translations, DT9804 or DT9826) when required. Digitized data were linked and stored in time series using Intensive Care Monitoring (ICM+) software (Cambridge Enterprise Ltd, Cambridge, UK).

Physiologic data cleaning and processing

All high-resolution physiologic data were cleared manually by qualified personnel utilizing ICM+ software. This was done without knowledge of study objectives or patient demographic data to minimize bias. This included removal of periods when the EVD was open to drainage, identified by complete loss of ICP waveform.

Following artifact clearing, data were down-sampled utilizing a 10-s non-overlapping moving average filter to eliminate high-frequency fluctuations in these parameters and focus on vasogenic slow-wave fluctuations associated with cerebral vasomotion [17, 34]. Next, CVR indices were derived utilizing 300 s window Pearson correlations between surrogates of CBV (ICP or rSO₂) and surrogates of driving pressure (ABP or CPP), continuously updating every minute. Utilizing this method, PRx was derived (correlation between ICP and ABP) along with two variations of the cerebral oxygen index: COx (correlation between rSO₂ and CPP) and COx_a (correlation between rSO₂ and ABP). ICP, ABP, rSO₂, PRx, COx, and COx_a were exported as minute-by-minute comma-separated values (.csv) files for each patient. No interpolation of missing data was performed as it was not required for subsequent analysis.

To provide the best quality data and simplify analysis, a single side/channel of rSO₂ was utilized for analysis and was selected to avoid interference from extravascular blood (scalp, epidural, subdural, or intraparenchymal hematomas/contusions) as based on radiographic imaging. If a subject had evidence of bilateral extravascular blood, they were excluded from analysis. If no imaging data were available, the side with the longest duration of rSO₂ recording was selected to maximize data while maintaining a single NIRS channel. It was felt that averaging channels would introduce too much variability in the data during periods when one channel would drop out, which is a frequent occurrence in the setting of trauma.

Physiologic data analysis and statistical methods

R statistical software (Version 4.3.1, R Foundation for Statistical Computing, Vienna, Austria) was utilized for all data analysis leveraging the *tidyverse* and *fmsb* packages. OpenBLAS (Version 0.3.20, Institute of Software, Chinese Academy of Sciences, Beijing, China) was utilized for the Basic Linear Algebra Subprograms (BLAS) and the Linear Algebra Package (LAPACK) to improve multithreaded computational performance.

Patients were categorized based on survival at 6-months and based on favorable (GOSE 5–8) or unfavorable (GOSE 1–4) clinical outcome at 6-months. Mean values of ICP, rSO₂, PRx, COx, and COx_a were computed for each patient over the course of their entire recording period in ICU. Physiologic and demographic data were summarized for the entire cohort based on median values and interquartile ranges (IQR), or number of subjects, where appropriate.

Demographic and mean physiologic data were compared between alive/dead and favorable/unfavorable groupings utilizing Mann–Whitney U and chi-squared testing. Next, univariate logistic regression analysis was performed to determine the prognostic utility of averages of the physiologic parameters in isolation. This was followed by multivariable logistic regression analysis to characterize the prognostic value of the various physiologic parameters in and above a base model comprising of known clinical and radiographic prognostic indicators from standard prognostic models (age, admission GCS, admission pupil exam, and Marshall CT score) [35]. For the univariate and multivariable regression analyses, area under the receiver operating characteristic curve (AUC), Akaike information criterion (AIC), and Nagelkerke R² values were also determined to help compare the various models. Given the exploratory nature of this study, alpha was set to 0.05 without correction for multiple comparisons.

Following analyses previously reported in the multimodal monitoring TBI literature, derivation of threshold values of rSO₂, COx, and COx_a, at which survival and favorable outcomes worsened, was attempted [23, 24, 36]. Sequential 2×2 tables were generated based on patient outcome (either alive/dead or favorable/unfavorable) and whether the average physiologic parameter was above or below threshold. Sequential threshold values were utilized incrementing them by 0.05 for COx and COx_a and by 5% for rSO₂. For all three physiologic parameters, Pearson's chi-squared values were calculated for the 2×2 tables generated at each threshold. For each parameter examined, the threshold value that produced the largest statistically significant chi-squared value was deemed to have the best discriminative value.

While average values over a recording period may be useful prognostically, identification of thresholds for which percent time above/below is most discriminative may help better inform bedside management. To identify these exposure-based thresholds, the percentage time below rSO₂ threshold and above COx and COx_a threshold was calculated for each subject. Sequential threshold values were again utilized incrementing them by 0.05 for COx and COx_a and by 5% for rSO₂. A series of univariate logistic regressions were performed for both survival and favorable outcome (Survival~Percent time over COx Threshold, Survival~Percent time over COx_a Threshold, Survival~Percent time below rSO₂ Threshold, Favorable Outcome~Percent time over COx Threshold, Favorable Outcome~Percent time over COx_a Threshold, Favorable Outcome~Percent time below rSO₂ Threshold) with the various threshold values. To determine the ideal threshold for each parameter, the area under the receiver operator characteristic curve (AUC) was calculated for each model and compared. The threshold values that produced the highest AUC were deemed to have the best discriminative value.

Results

Cohort demographics

In total, 129 subjects from the CAHR-TBI database were included in the study with admission to hospital between November 2016 and December 2022. This included 18 patients from Foothills Medical Centre (University of Calgary), 87 patients from Health Sciences Centre Winnipeg (University of Manitoba), 22 patients from Maastricht University Medical Center (University of Maastricht), and 2 patients from Vancouver General Hospital (University of British Columbia). In total 751,060 min of unique physiologic recording was collected with a median recording duration of 4578 min (IQR: 2346 to 8275 min) per subject. A 1-h sample of the 10-s-by-10-s moving averaged physiologic data and minute-by-minute derived CVR indices can be seen in Fig. 1. Radiographic data to identify extravascular blood for the purposes of selecting rSO₂ channel side were available in 87 subjects. The right rSO₂ channel was selected in 102 subjects, while the left channel was selected in 27 subjects. Demographic and physiologic data for the cohort are summarized in Table 1.

The results of the Mann–Whitney-U testing between alive/dead and favorable/unfavorable groups can be seen in Table 2. Age was found to be statistically higher in those who died and those who had an unfavorable outcome. GCS on admission was found to be lower in those who had an unfavorable outcome at follow up. This trend was seen when examining survival; however, this did not reach statistical significance. All measures of CVR




Fig. 1 A sample of the 10-s-by-10-s recorded parameters arterial blood pressure (ABP), intracranial pressure (ICP), and left and right regional cerebral oxygen (L rSO₂ and R rSO₂) can be seen in the first four series. The minute-by-minute derived cerebrovascular reactivity indices (PRx—pressure reactivity index, L COx—left cerebral oxygen index based on cerebral perfusion pressure, R COx—right cerebral oxygen index based on cerebral perfusion pressure, L COx_a—left cerebral oxygen index based on ABP, R COx_a—right cerebral oxygen index based on ABP) can be seen in the lower five series. Note that all five CVR indices trend well with each other

(PRx, COx, COx_a) were found to be statistically higher in those who died. While PRx and COx trended toward being higher in those with an unfavorable outcome than those with a favorable one, this did not reach statistical significance. Finally, of note, rSO₂ was no different across survival or clinical outcome groups.

Threshold value determination

There was no statistically significant discriminative threshold of average rSO₂ for survival or favorable outcome. In Fig. 2A and B, +0.2 was the threshold for average COx that produced the best statistically significant discriminative value for both favorable outcome and survival ($\chi^2=6.11$, $p=0.013$; $\chi^2=9.57$, $p=0.0020$, respectively). Similarly, in Fig. 2C and D +0.2 also produced the most discriminative threshold for average COx_a for both survival and favorable outcome ($\chi^2=9.08$, $p=0.0026$; $\chi^2=13.04$, $p<0.001$, respectively). Full results can be seen in Additional file 1.

There was no threshold value of rSO₂ where percentage time below was a statistically significant univariate logistic regressor for either survival or favorable outcome. Regarding COx, a threshold value of -0.05 produced the best performing univariate logistic model with percent time over threshold as a significant regressor for survival ($p<0.001$, AUC=0.70, 95% CI 0.60–0.79) and for favorable outcome ($p=0.003$, AUC=0.65, 95% CI 0.55–0.79). Similarly, percent time over a threshold COx_a value of -0.05 as a univariate regressor was found to produce the best performing model for survival ($p<0.001$, AUC=0.70, 95% CI 0.61–0.80) and favorable outcome ($p=0.002$, AUC=0.65, 95% CI 0.56–0.75). Full results can be seen in Additional file 2.

Univariate and multivariable logistic regression analysis

Through the univariate logistic regression analysis, average rSO₂ was again not found to be prognostic as

Table 1 Patient demographics and cerebral physiology

| Demographic parameter | Median or number of patients N = 129 |
|---|---|
| Age (IQR) | 41 (28–57) |
| Male, sex (%) | 102 (79.1) |
| Admission GCS (IQR) | 6 (4–8) |
| Admission pupils | |
| Bilaterally reactive (%) | 91 (70.5) |
| Unilaterally reactive (%) | 20 (15.5) |
| Bilaterally unreactive (%) | 18 (14.0) |
| N/A (%) | 0 (0.0) |
| Marshall CT classification | |
| I (%) | 2 (1.6) |
| II (%) | 31 (24.0) |
| III (%) | 30 (23.3) |
| IV (%) | 19 (14.7) |
| V (%) | 46 (35.7) |
| VI (%) | 0 (0.0) |
| N/A, n (%) | 1 (0.8) |
| Follow-up 6-month GOSE | |
| 1 (%) | 51 (39.5) |
| 2 (%) | 1 (0.8) |
| 3 (%) | 7 (5.4) |
| 4 (%) | 2 (1.6) |
| 5 (%) | 12 (9.3) |
| 6 (%) | 14 (10.9) |
| 7 (%) | 28 (21.7) |
| 8 (%) | 11 (8.5) |
| N/A, n (%) | 3 (2.3) |
| Subject average ICP in mmHg (IQR) | 10.0 (6.9–13.6) |
| Subject average CPP in mmHg (IQR) | 73.5 (69.1–79.6) |
| Subject average rSO ₂ in % (IQR) | 69.7 (64.1–75.1) |
| Subject average PRx (IQR) | 0.14 (0.02–0.25) |
| Subject average COx (IQR) | 0.02 (-0.04–0.08) |
| Subject average COx _a (IQR) | 0.04 (0.01–0.11) |
| Duration of ICP recording (days) | 2.8 (1.1–4.9) |
| Duration of CPP recording (days) | 2.7 (1.0–4.7) |
| Duration of rSO ₂ recording (days) | 2.5 (1.1–4.9) |
| Subject average PaCO ₂ (mmHg)* | 37 (34–40) |
| Subject average PaO ₂ (mmHg)* | 111 (89–140) |

COx Cerebral Oxygen Index Based on Cerebral Perfusion Pressure; COx_a Cerebral Oxygen Index Based on Arterial Blood Pressure; CPP Cerebral Perfusion Pressure; CT Computed Tomography; GCS Glasgow Coma Scale; GOSE Extended Glasgow Outcome Scale; ICP Intracranial Pressure; IQR Interquartile Range; PaCO₂ Partial Pressure of Arterial Carbon Dioxide; PaO₂ Partial Pressure of Arterial Oxygen; PRx Pressure Reactivity Index; and rSO₂ Regional Cerebral Oxygen Saturation

*Data only available from 87 patients

a stand-alone parameter. Conversely, subject average values of ICP, PRx, COx, and COx_a were all found to be statistically significant predictors of survival and

favorable outcome. Of note, average COx performed the best as a univariate regressor with the greatest degree of variance in outcome explained as demonstrated by the Nagelkerke R². Generally, rSO₂ based indices of CVR were prognostically equivalent to or better than PRx. The full results of the univariate logistic regression analysis can be found in Table 3.

Through the multivariable logistic regression analysis, it was found the addition of rSO₂ to the baseline model failed to improve model performance and did not account for any additional variance in outcomes. While AUC values were similar for all models that utilized averages parameters over the recording period, Nagelkerke R² values were markedly improved when the base model was augmented with average ICP, PRx, COx, or COx_a, indicating an increased ability of the model to explain outcome variance. Average ICP, COx, and COx_a remained independent predictors of survival when added to the base model, while, of these, only average ICP and average COx were independent predictors of favorable outcome. Interestingly, the multivariate models that performed the best were those that incorporated percent time over the previously determined COx and COx_a threshold of – 0.05. Of note, average PRx was neither an independent predictor of survival nor favorable outcome when base model parameters were accounted for. The full results of the multivariable logistic regression analysis can be found in Table 4.

Discussion

Through this multi-institutional retrospective cohort study, the prognostic utility of various NIRS-based parameters has been assessed. This was done using the largest multicenter database, to our knowledge, with high-frequency rSO₂, ICP and ABP physiologic streams concurrently monitored. Given the relatively large cohort size and multi-institutional nature of the cohort, the findings of this study are likely widely generalizable to TBI populations. A key finding of this study is the prognostic utility of rSO₂-based measures of CVR. These NIRS-based indices performed equally to the more commonly utilized ICP-based index PRx. This is in keeping with recent work indicating that PRx and COx/COx_a have a linear relationship with one another [37]. COx and COx_a, like PRx, have a range from – 1 to +1 with higher values indicative of increased correlation of CBV and driving pressure and essentially disruption of CVR. Both COx and COx_a were found to have a grand mean threshold value of 0.2, above which outcomes worsened when the entire recording period was considered. This is consistent with previous large animal studies that found COx and COx_a values above the range of 0.3–0.5 to be associated with a complete loss of cerebral autoregulation

Table 2 Comparison of demographic and physiologic parameters across alive/dead and favorable/unfavorable groups

| Variable | Favorable/unfavorable | | p value | Alive/dead | | p value |
|--|--|--|---------------|--|---|-------------------|
| | Favorable median (IQR) or number (%) N=67 | Unfavorable median (IQR) or number (%) N=62 | | Alive median (IQR) or number (%) N=78 | Dead median (IQR) or number (%) N=51 | |
| Age | 38.5 (27.0–50.0) | 49.0 (32.0–66.0) | 0.0040 | 38.0 (25.3–38.3) | 57.0 (35.3–66.8) | <0.0010 |
| Male sex | 51 (77.3) | 50 (80.6) | 0.64 | 61 (78.2) | 41 (80.4) | 0.77 |
| Admission GCS | 7.0 (5.0–8.0) | 5.0 (3.0–8.0) | 0.010 | 7.0 (5.0–8.0) | 5.0 (3.0–8.5) | 0.090 |
| Number of reactive pupils on admission | 2.0 (2.0–2.0) | 2.0 (1.0–2.0) | 0.060 | 2.0 (1.3–2.0) | 2.0 (1.0–2.0) | 0.23 |
| Marshall CT Score | 3.0 (3.0–5.0) | 4.0 (2.0–5.0) | 0.82 | 3 (2.3–5.0) | 4.0 (2.3–5.0) | 0.28 |
| Subject average PRx | 0.10 (0.01–0.21) | 0.15 (0.03–0.29) | 0.080 | 0.08 (0.01–0.21) | 0.18 (0.04–0.29) | 0.040 |
| Subject average COx | 0.01 (– 0.05 to 0.07) | 0.03 (– 0.03 to 0.11) | 0.080 | 0.01 (–0.05–0.05) | 0.03 (– 0.02 to 0.14) | 0.010 |
| Subject average COx_a | 0.04 (0.00–0.10) | 0.05 (0.01–0.12) | 0.18 | 0.03 (0.00–0.09) | 0.07 (0.01–0.13) | 0.030 |
| Subject average rSO ₂ | 70.2 (63.2–75.9) | 69.5 (64.2–74.9) | 0.94 | 69.5 (64.3–74.7) | 70.3 (62.6–76.3) | 0.98 |

Bolded p values indicate statistical significance (p < 0.05)

COx Cerebral Oxygen Index Based on Cerebral Perfusion Pressure; COx_a Cerebral Oxygen Index Based on Arterial Blood Pressure; CT Computed Tomography; GCS Glasgow Coma Scale; ICP Intracranial Pressure; IQR Interquartile Range; PRx Pressure Reactivity Index; and rSO₂ Regional Cerebral Oxygen Saturation




Fig. 2 Plots of chi-square results for incremental thresholds of the cerebral perfusion pressure variant of the cerebral oxygen index (COx) and the arterial blood pressure variant of the cerebral oxygen index (COx_a). Panels **A** and **C** display the discriminative value of thresholds for favorable outcomes for average COx and COx_a, respectively. Panels **B** and **D** display the discriminative value of thresholds for survival for average COx and COx_a, respectively. Red points indicate chi-square values that reached statistical significance (p < 0.05). Of note, while COx and COx_a theoretically extend from – 1 to + 1, in this dataset average values extended over a more limited range

[31, 38–40]. Given that this was the threshold found when values were averaged over the course of monitoring, a value of 0.2 may indicate a significant period of exposure to dysfunctional cerebral autoregulation

resulting in poor clinical outcomes. Prior studies examining outcome associated thresholds with continuous ICP and transcranial Doppler (TCD)-based indices of CVR have also identified values in the range of 0.2 [22–24,

Table 3 Univariate logistic regression

| Regressor | Favorable vs unfavorable outcome | | | | Alive vs dead | | | |
|----------------------------------|----------------------------------|--------|---------------------------|--------------|------------------|--------|---------------------------|---------------|
| | AUC (95% CI) | AIC | Nagelkerke R ² | p value | AUC (95% CI) | AIC | Nagelkerke R ² | p value |
| Subject average ICP | 0.59 (0.49–0.69) | 174.61 | 0.055 | 0.027 | 0.61 (0.51–0.72) | 168.58 | 0.077 | 0.010 |
| Subject average PRx | 0.59 (0.49–0.69) | 171.71 | 0.044 | 0.047 | 0.61 (0.51–0.71) | 167.13 | 0.062 | 0.019 |
| Subject average COx | 0.59 (0.49–0.69) | 172.85 | 0.060 | 0.021 | 0.63 (0.53–0.73) | 163.57 | 0.117 | 0.0016 |
| Subject average COx _a | 0.57 (0.47–0.67) | 177.00 | 0.044 | 0.046 | 0.61 (0.51–0.71) | 168.32 | 0.089 | 0.0059 |
| Subject average rSO ₂ | 0.50 (0.40–0.60) | 181.13 | 0.002 | 0.66 | 0.50 (0.39–0.60) | 176.84 | 0.003 | 0.59 |

Bolded *p* values indicate statistical significance ($p < 0.05$)

AIC Akaike Information Criterion; AUC Area Under the Receiver Operating Characteristic Curve; COx Cerebral Oxygen Index Based on Cerebral Perfusion Pressure; COx_a Cerebral Oxygen Index Based on Arterial Blood Pressure; CI Confidence Interval; ICP Intracranial Pressure; PRx Pressure Reactivity Index; and rSO₂ Regional Cerebral Oxygen Saturation

Table 4 Multivariable logistic regression

| Model | Favorable vs unfavorable outcome | | | | Alive vs dead | | | |
|---|----------------------------------|--------|---------------------------|---------------------------------|------------------|--------|---------------------------|---------------------------------|
| | AUC (95% CI) | AIC | Nagelkerke R ² | p value of additional parameter | AUC (95% CI) | AIC | Nagelkerke R ² | p value of additional parameter |
| Base model | 0.73 (0.64–0.82) | 164.50 | 0.195 | N/A | 0.74 (0.64–0.83) | 155.64 | 0.231 | N/A |
| Base model + ICP | 0.75 (0.67–0.84) | 158.23 | 0.258 | 0.024 | 0.78 (0.69–0.86) | 144.99 | 0.332 | 0.003 |
| Base Model + PRx | 0.75 (0.66–0.83) | 157.00 | 0.238 | 0.115 | 0.76 (0.67–0.85) | 149.26 | 0.277 | 0.080 |
| Base model + average COx | 0.76 (0.67–0.84) | 156.87 | 0.260 | 0.038 | 0.76 (0.68–0.85) | 146.97 | 0.310 | 0.010 |
| Base model + average COx _a | 0.75 (0.67–0.84) | 162.59 | 0.230 | 0.059 | 0.76 (0.67–0.85) | 151.74 | 0.283 | 0.021 |
| Base Model + percent Time COx > - 0.05 | 0.77 (0.69–0.85) | 154.32 | 0.282 | 0.010 | 0.79 (0.70–0.87) | 142.94 | 0.343 | 0.002 |
| Base Model + percent Time COx _a > - 0.05 | 0.76 (0.68–0.85) | 157.79 | 0.271 | 0.006 | 0.79 (0.70–0.87) | 145.32 | 0.336 | <0.001 |
| base model + rSO ₂ | 0.73 (0.64–0.82) | 166.45 | 0.195 | 0.830 | 0.74 (0.65–0.83) | 157.64 | 0.231 | 0.935 |

Bolded *p* values indicate statistical significance ($p < 0.05$)

Base model comprising of known clinical and radiographic prognostic indicators from standard prognostic models (age, admission GCS, admission pupil exam, and Marshall CT score) [35]

The base model included age, admission Glasgow Coma Scale, admission pupil reactivity, and Marshall computed tomography scale

AIC Akaike Information Criterion; AUC Area Under the Receiver Operating Characteristic Curve; COx Cerebral Oxygen Index Based on Cerebral Perfusion Pressure; COx_a Cerebral Oxygen Index Based on Arterial Blood Pressure; CI Confidence Interval; ICP Intracranial Pressure; PRx Pressure Reactivity Index; and rSO₂ Regional Cerebral Oxygen Saturation

41–43]. These findings are also consistent with past studies in humans that have found that NIRS-based indices of CVR track strongly with ICP-based indices [15, 32, 37, 44–46].

Even just exposure to periods of disrupted CVR may be associated with worse clinical outcomes [3]. When trying to identify an exposure-based threshold, percent time over - 0.05 was found to have the best discriminative value for both COx and COx_a. This may be a more clinically useful threshold when developing CVR guided management at the bedside. While an average COx or COx_a greater than 0.2 may represent gross CVR dysfunction, an increased proportion of time above values of - 0.05 may expose the brain to deleterious effect of CVR

dysfunction. It should be noted that the present study represents the first such evidence of an outcome association of these NIRS-based indices in TBI. Previous studies examining the outcome association of NIRS-based indices in TBI were likely underpowered [7].

Another notable finding of this study is that rSO₂, as a raw NIRS parameter, failed to demonstrate any prognostic value in both univariate and multivariable analysis. Further, there was no identifiable threshold value of rSO₂ at which outcomes following TBI worsened. This is somewhat surprising given the existing body of evidence indicating a relationship between rSO₂ and measures of CBF or CBV [8]. A key factor to take into consideration is that in these studies it was typical that relative changes

in CBV/CBF were associated with changes in rSO_2 . In the present study, absolute values of rSO_2 were examined as a prognostic tool. This may explain why rSO_2 -based indices had more prognostic utility than raw rSO_2 as these indices relay primary on changes in rSO_2 mathematically as they are derived utilizing a Pearson correlation coefficient.

A key takeaway from this study is that rSO_2 as a raw absolute parameter provides little, if any prognostic value in the ICU. This is consistent with recent studies that found high-resolution rSO_2 signals to have differing statistical properties to more established monitoring modalities in moderate-to-severe TBI including brain tissue oxygenation ($PbtO_2$), CPP, and ICP, as well as various measures of CVR [47, 48]. It should be noted that in alternative settings, such as intraoperative monitoring, change in rSO_2 is viewed as a more reliable metric of cerebral hypoxia and ischemic risk [49, 50]. However, in the setting of moderate and severe TBI, change in rSO_2 is a far less clear concept. Identifying an appropriate baseline in this setting is difficult given the confounders of already present cerebral injury and potentially concurrent multi-system trauma.

Study limitations

Interpretation of the findings of this study should be taken with consideration of its limitations. First and foremost, this was a retrospective observational study where not all possible confounders were able to be accounted for. Measures of blood oxygen content such as systemic oxygen saturation (SpO_2) and arterial partial pressure of oxygen (PaO_2) along with other influential parameters such as end-tidal carbon dioxide ($ETCO_2$) and vasoactive medication use were not available on a minute-by-minute basis. These are factors that can also modify rSO_2 signals, and therefore rSO_2 -based indices of CVR [51]. While in the ICU setting these parameters are typically well controlled, the effect of these factors was not directly accounted for. Similarly, the degree of systemic injury or decisions surrounding withdrawal of care were not accounted for in each subject as this data was not available. This obviously neglects the effects these factors may have had on clinical outcome.

Secondly, only a single NIRS channel per patient was utilized for analysis. This was done to simplify the nature of the analysis but does mean that hemispheric differences in rSO_2 , COx, or COx_a were not examined. Additionally, the selection of which channel to use was not always able to be guided by radiographic evidence of disruptive artifacts such as extravascular blood.

Finally, analysis was conducted over the entire recording period of relevant physiologic parameters. This does mean that the temporal evolution of these parameters was not fully considered.

Future directions

Prior to abandoning rSO_2 as a parameter to guide management, further work will be required to examine if changes in rSO_2 are of greater prognostic value. Consideration will need to be given to the various challenges in establishing an appropriate baseline. This will inform how best to utilize rSO_2 at the bedside to guide care as the results of this study indicate that raw values are likely of little value. Ultimately, rSO_2 informed management of TBI should be examined in a prospective randomized fashion to determine if this modality is a useful adjunct to more established monitoring methods.

Regarding the rSO_2 -based indices of CVR, this study has indicated that there may be significant promise in their role as a prognostic tool. This will need to be further validated in large prospective studies. Patient-specific optimal CPP targets based on COx and COx_a warrant further exploration. Whether a threshold of 0.2 or -0.05 would produce better clinical outcomes when utilized to optimize CPP goals will need to be evaluated in a large multicenter prospective trial.

Finally, given the possible entirely noninvasive nature of COx_a, examination of the evolution of dysfunctional CVR following TBI should be possible into the chronic phase [52, 53]. A more thorough understanding of the trajectory of these parameters may help to not only guide management of this population in the acute phase but also through into the rehabilitation phase.

Conclusion

In this study, the prognostic utility of rSO_2 and rSO_2 -based parameters of CVR was explored in the setting of moderate-to-severe TBI. While absolute rSO_2 as a raw parameter was found to have negligible prognostic value, COx and COx_a were both found to contain prognostic information. Beyond this, a grand mean threshold value of 0.2 was identified, for both COx and COx_a, above which outcomes markedly worsened. Additionally, -0.05 for COx and COx_a was identified as a threshold value where the percentage of time above this threshold produced the best discriminative values. This work opens the door for further exploration of NIRS-based indices of CVR as a possible prognostic tool. Further work is needed to validate these findings and explore the possibly of COx/COx_a driven management of TBI in both the acute and chronic phases of recovery from TBI.

Abbreviations

| | |
|----------|--|
| ABP | Arterial blood pressure |
| AIC | Akaike information criterion |
| AUC | Area under the receiver operating characteristic curve |
| BLAS | Basic linear algebra subprograms |
| CAHR-TBI | Canadian High-Resolution TBI |
| CBF | Cerebral blood flow |

| | |
|-------------------|--|
| CBV | Cerebral blood volume |
| CI | Confidence interval |
| COx | Cerebral oxygen index with cerebral perfusion pressure |
| COx _a | Cerebral oxygen index with arterial blood pressure |
| CPP | Cerebral perfusion pressure |
| csv | Comma-separated values |
| CT | Computed tomography |
| CVR | Cerebrovascular reactivity |
| GCS | Glasgow Coma Scale |
| GOSE | Extended Glasgow Outcome Scale |
| ICP | Intracranial pressure |
| ICU | Intensive care units |
| IQR | Interquartile ranges |
| LAPACK | Linear algebra package |
| NIRS | Near-infrared spectroscopy |
| PaCO ₂ | Partial pressure of arterial carbon |
| PaO ₂ | Partial pressure of arterial oxygen |
| PbtO ₂ | Brain tissue oxygenation |
| PRx | Pressure reactivity index |
| rSO ₂ | Regional cerebral oxygen saturation |
| SpO ₂ | Systemic oxygen saturation |
| TBI | Traumatic brain injury |
| TCD | Transcranial Doppler |

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13054-024-04859-6>.

Additional file 1. Results for grand average threshold search for rSO₂, COx, and COx_a

Additional file 2. Results for percent time over threshold search for rSO₂, COx, and COx_a

Acknowledgements

We would like to acknowledge the patients and staff of the Foothills Medical Centre, Health Sciences Centre Winnipeg, Maastricht University Medical Center and the Vancouver General Hospital, without which the data from this study would not be possible.

Author contributions

Study conception and design were done by ATG and FAZ. Data collection was performed by ATG, LF, DG, LVI, JT, MA, KYS, CG, AHD, and FAZ. Data analysis and preparation of the first draft of the manuscript were performed by ATG. All authors contributed to editing and revising the manuscript. All authors read and approved the final manuscript.

Funding

This work was directly supported the University of Manitoba Endowed Manitoba Public Insurance (MPI) Chair in Neuroscience, the Natural Sciences and Engineering Research Council of Canada (NSERC) (DGECR-2022-00260, RGPIN-2022-03621, ALLRP-578524-22 and ALLRP-576386-22, ALLRP 586244-23). FAZ is supported through the University of Manitoba Endowed Manitoba Public Insurance (MPI) Chair in Neuroscience/TBI Research Endowment, NSERC, Canadian Institutes of Health Research (CIHR), the MPI Neuroscience Research Operating Fund, the Health Sciences Centre Foundation Winnipeg, the Canada Foundation for Innovation (CFI) (Project #: 38583), Research Manitoba (Grant #: 3906 and 5429) and the University of Manitoba VPRI Research Investment Fund (RIF). LF is supported through a Research Manitoba PhD Fellowship, the Brain Canada Thompkins Travel Scholarship, NSERC and the Graduate Enhancement of Tri-Council Stipends (GETS)—University of Manitoba. AG is supported through a CIHR Fellowship (Grant #: 472286). KYS is supported through the University of Manitoba R.G. and E.M. Graduate Fellowship (Doctoral) in Biomedical Engineering, and the University of Manitoba MD/PhD program, and NSERC CGS-D (CGS D-579021-2023). EPT acknowledges funding support from Karolinska Institutet Funds (2022-01576), The Swedish Brain Foundation (FO2023-0124), The Swedish Society of Medicine (SLS-985504), Region Stockholm ALF (FoUI-962566), and Region Stockholm Clinical Research Appointment (ALF Klinisk Forskare, FoUI-981490). RR is supported by funding

grants from The Swedish Cultural Foundation in Finland, Finska Läkaresällskapet, and a state funded research grant (Helsinki university hospital).

Availability of data and materials

The datasets analyzed and code utilized during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Local ethics approval for all aspects of data collection and anonymous data transfer between centers was obtained from the individual local research ethics boards (H2017:181, H2017:188, H2020:118, B2023:001 H20-03,759 and REB20-0482). Given that the study was noninvasive and did not deviate from the standard of care, a waiver of consent was obtained from the Biomedical Research Ethics Boards for included participants.

Consent to publication

Not applicable.

Competing interests

The authors have no competing interests to declare.

Author details

¹Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada. ²Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. ³Department of Biomedical Engineering, Price Faculty of Engineering, University of Manitoba, Winnipeg, MB, Canada. ⁴Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada. ⁵Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. ⁶Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. ⁷Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁸Department of Intensive Care, Maastricht University Medical Center+, Maastricht, The Netherlands. ⁹School of Mental Health and Neurosciences, University Maastricht, Maastricht, The Netherlands. ¹⁰Section of Neurosurgery, Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. ¹¹Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. ¹²Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. ¹³Section of Critical Care, Department of Medicine, University of Montreal, Montreal, QC, Canada. ¹⁴Department of Critical Care Medicine, University of Calgary, Calgary, AB, Canada. ¹⁵Centre on Aging, University of Manitoba, Winnipeg, Canada. ¹⁶Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.

Received: 13 December 2023 Accepted: 2 March 2024

Published online: 14 March 2024

References

- Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. *Neurosurgery*. 2017;80:6–15. <https://doi.org/10.1227/NEU.0000000000001432>.
- Chesnut R, Aguilera S, Buki A, et al. A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). *Intensive Care Med*. 2020;46:919–29. <https://doi.org/10.1007/s00134-019-05900-x>.
- Donnelly J, Czosnyka M, Adams H, et al. Twenty-five years of intracranial pressure monitoring after severe traumatic brain injury: a retrospective, single-center analysis. *Neurosurg*. 2019;85:E75–82. <https://doi.org/10.1093/neuros/nyy468>.
- Le Roux P, Menon DK, Citerio G, et al. Consensus Summary Statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: A statement for healthcare professionals from the Neurocritical Care Society and the European Society of

- Intensive Care Medicine. *Neurocrit Care*. 2014;21:1–26. <https://doi.org/10.1007/s12028-014-0041-5>.
5. Jöbsis FF. Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. *Science*. 1977;198:1264–7. <https://doi.org/10.1126/science.929199>.
 6. Jo Bsis-Vandervliet FF. Discovery of the near-infrared window into the body and the early development of near-infrared spectroscopy. *J Biomed Opt*. 1999;4:392–6. <https://doi.org/10.1117/1.429952>.
 7. Mathieu F, Khellaf A, Ku JC, et al. Continuous near-infrared spectroscopy monitoring in adult traumatic brain injury: a systematic review. *J Neurosurg Anesthesiol*. 2020;32:288–99. <https://doi.org/10.1097/ANA.0000000000000620>.
 8. Gomez A, Sainbhi AS, Froese L, et al. The quantitative associations between near infrared spectroscopic cerebrovascular metrics and cerebral blood flow: a scoping review of the human and animal literature. *Front Physiol*. 2022;13:934731. <https://doi.org/10.3389/fphys.2022.934731>.
 9. Czosnyka M, Smielewski P, Piechnik S, et al. Cerebral autoregulation following head injury. *J Neurosurg*. 2001;95:756–63. <https://doi.org/10.3171/jns.2001.95.5.0756>.
 10. Rangel-Castilla L, Gasco J, Nauta HJW, et al. Cerebral pressure autoregulation in traumatic brain injury. *Neurosurg Focus*. 2008;25:E7. <https://doi.org/10.3171/FOC.2008.25.10.E7>.
 11. Armstead WM. Cerebral blood flow autoregulation and dysautoregulation. *Anesthesiol Clin*. 2016;34:465–77. <https://doi.org/10.1016/j.anclin.2016.04.002>.
 12. Czosnyka M, Miller C. Monitoring of cerebral autoregulation. *Neurocrit Care*. 2014;21:95–102. <https://doi.org/10.1007/s12028-014-0046-0>.
 13. Czosnyka M, Smielewski P, Kirkpatrick P, et al. Continuous assessment of the cerebral vasomotor reactivity in head injury. *Neurosurgery*. 1997;41:11–9. <https://doi.org/10.1097/00006123-199707000-00005>.
 14. Steiner LA, Czosnyka M, Piechnik SK, et al. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. *Crit Care Med*. 2002;30:733–8. <https://doi.org/10.1097/00003246-200204000-00002>.
 15. Zweifel C, Lavinio A, Steiner LA, et al. Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury. *FOC*. 2008;25:E2. <https://doi.org/10.3171/FOC.2008.25.10.E2>.
 16. Budohoski KP, Czosnyka M, de Riva N, et al. The relationship between cerebral blood flow autoregulation and cerebrovascular pressure reactivity after traumatic brain injury. *Neurosurgery*. 2012;71:652–61. <https://doi.org/10.1227/NEU.0b013e318260feb1>.
 17. Howells T, Johnson U, McKelvey T, Enblad P. An optimal frequency range for assessing the pressure reactivity index in patients with traumatic brain injury. *J Clin Monit Comput*. 2015;29:97–105. <https://doi.org/10.1007/s10877-014-9573-7>.
 18. Lang EW, Kasprovicz M, Smielewski P, et al. Short pressure reactivity index versus long pressure reactivity index in the management of traumatic brain injury. *J Neurosurg*. 2015;122:588–94. <https://doi.org/10.3171/2014.10.JNS14602>.
 19. Adams H, Donnelly J, Czosnyka M, et al. Temporal profile of intracranial pressure and cerebrovascular reactivity in severe traumatic brain injury and association with fatal outcome: An observational study. *PLoS Med*. 2017;14:e1002353. <https://doi.org/10.1371/journal.pmed.1002353>.
 20. Svedung Wettervik T, Howells T, Enblad P, Lewén A. Temporal neurophysiological dynamics in traumatic brain injury: role of pressure reactivity and optimal cerebral perfusion pressure for predicting outcome. *J Neurotrauma*. 2019;36:1818–27. <https://doi.org/10.1089/neu.2018.6157>.
 21. Zeiler FA, Ercole A, Cabelreira M, et al. Univariate comparison of performance of different cerebrovascular reactivity indices for outcome association in adult TBI: a CENTER-TBI study. *Acta Neurochir*. 2019;161:1217–27. <https://doi.org/10.1007/s00701-019-03844-1>.
 22. Stein K, Froese L, Sekhon MS, et al. Intracranial pressure-derived cerebrovascular reactivity indices and their critical thresholds: a canadian high resolution-TBI (CAHR-TBI) validation study. *J Neurotrauma*. 2023. <https://doi.org/10.1089/neu.2023.0374>.
 23. Sorrentino E, Diedler J, Kasprovicz M, et al. Critical thresholds for cerebrovascular reactivity after traumatic brain injury. *Neurocrit Care*. 2012;16:258–66. <https://doi.org/10.1007/s12028-011-9630-8>.
 24. Zeiler FA, Donnelly J, Smielewski P, et al. Critical thresholds of intracranial pressure-derived continuous cerebrovascular reactivity indices for outcome prediction in noncraniectomized patients with traumatic brain injury. *J Neurotrauma*. 2018;35:1107–15. <https://doi.org/10.1089/neu.2017.5472>.
 25. Donnelly J, Czosnyka M, Adams H, et al. Pressure reactivity-based optimal cerebral perfusion pressure in a traumatic brain Injury Cohort. *Acta Neurochir Suppl*. 2018;126:209–12. https://doi.org/10.1007/978-3-319-65798-1_43.
 26. Howells T, Smielewski P, Donnelly J, et al. Optimal cerebral perfusion pressure in centers with different treatment protocols. *Crit Care Med*. 2018;46:e235–41. <https://doi.org/10.1097/CCM.0000000000002930>.
 27. Beqiri E, Smielewski P, Robba C, et al. Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: the COGITATE phase II study protocol. *BMJ Open*. 2019;9:e030727. <https://doi.org/10.1136/bmjopen-2019-030727>.
 28. Petkus V, Preiksaitis A, Chaleckas E, et al. Optimal cerebral perfusion pressure: targeted treatment for severe traumatic brain injury. *J Neurotrauma*. 2020;37:389–96. <https://doi.org/10.1089/neu.2019.6551>.
 29. Tas J, Beqiri E, van Kaam RC, et al. Targeting autoregulation-guided cerebral perfusion pressure after traumatic brain injury (COGITATE): a feasibility randomized controlled clinical trial. *J Neurotrauma*. 2021;38:2790–800. <https://doi.org/10.1089/neu.2021.0197>.
 30. Smielewski P, Kirkpatrick P, Minhas P, et al. Can cerebrovascular reactivity be measured with near-infrared spectroscopy? *Stroke*. 1995;26:2285–92. <https://doi.org/10.1161/01.STR.26.12.2285>.
 31. Brady KM, Lee JK, Kibler KK, et al. Continuous time-domain analysis of cerebrovascular autoregulation using near-infrared spectroscopy. *Stroke*. 2007;38:2818–25. <https://doi.org/10.1161/STROKEAHA.107.485706>.
 32. Lee JK, Kibler KK, Benni PB, et al. Cerebrovascular reactivity measured by near-infrared spectroscopy. *Stroke*. 2009;40:1820–6. <https://doi.org/10.1161/STROKEAHA.108.536094>.
 33. Bernard F, Gallagher C, Griesdale D, et al. The Canadian high-resolution traumatic brain injury (CAHR-TBI) research collaborative. *Can J Neurol Sci*. 2020;47:551–6. <https://doi.org/10.1017/cjn.2020.54>.
 34. Fraser CD, Brady KM, Rhee CJ, et al. The frequency response of cerebral autoregulation. *J Appl Physiol*. 2013;115:52–6. <https://doi.org/10.1152/jappphysiol.00068.2013>.
 35. Wongchareon K, Thompson HJ, Mitchell PH, et al. IMPACT and CRASH prognostic models for traumatic brain injury: external validation in a South-American cohort. *Inj Prev*. 2020;26:546–54. <https://doi.org/10.1136/injuryprev-2019-043466>.
 36. Stein K, Froese L, Sekhon MS, et al. Intracranial pressure-derived cerebrovascular reactivity indices and their critical thresholds: A Canadian High Resolution-TBI (CAHR-TBI) Validation Study. *J Neurotrauma*. 2023. <https://doi.org/10.1089/neu.2023.0374>.
 37. Gomez A, Froese L, Bergmann TJG, et al. Non-invasive estimation of intracranial pressure-derived cerebrovascular reactivity using near-infrared spectroscopy sensor technology in acute neural injury: a time-series analysis. *Sensors*. 2024;24:499. <https://doi.org/10.3390/s24020499>.
 38. Brady KM, Mytar JO, Kibler KK, et al. Noninvasive autoregulation monitoring with and without intracranial pressure in the naive piglet brain. *Anesth Analg*. 2010;111:191–5. <https://doi.org/10.1213/ANE.0b013e3181e054ba>.
 39. Lee JK, Brady KM, Mytar JO, et al. Cerebral blood flow and cerebrovascular autoregulation in a swine model of pediatric cardiac arrest and hypothermia. *Crit Care Med*. 2011;39:2337–45. <https://doi.org/10.1097/CCM.0b013e318223b910>.
 40. Sainbhi AS, Froese L, Gomez A, et al. Continuous time-domain cerebrovascular reactivity metrics and discriminate capacity for the upper and lower limits of autoregulation: a scoping review of the animal literature. *Neurotrauma Rep*. 2021;2:639–59. <https://doi.org/10.1089/neur.2021.0043>.
 41. Sorrentino E, Budohoski KP, Kasprovicz M, et al. Critical thresholds for transcranial Doppler indices of cerebral autoregulation in traumatic brain injury. *Neurocrit Care*. 2011;14:188–93. <https://doi.org/10.1007/s12028-010-9492-5>.
 42. Zeiler FA, Cardim D, Donnelly J, et al. Transcranial doppler systolic flow index and ICP-derived cerebrovascular reactivity indices in traumatic brain injury. *J Neurotrauma*. 2018;35:314–22. <https://doi.org/10.1089/neu.2017.5364>.
 43. Riemann L, Beqiri E, Smielewski P, et al. Low-resolution pressure reactivity index and its derived optimal cerebral perfusion pressure in adult

- traumatic brain injury: a CENTER-TBI study. *Crit Care*. 2020;24:266. <https://doi.org/10.1186/s13054-020-02974-8>.
44. Zweifel C, Castellani G, Czosnyka M, et al. Noninvasive monitoring of cerebrovascular reactivity with near infrared spectroscopy in head-injured patients. *J Neurotrauma*. 2010;27:1951–8. <https://doi.org/10.1089/neu.2010.1388>.
 45. Zeiler FA, Donnelly J, Menon DK, et al. Continuous autoregulatory indices derived from multi-modal monitoring: each one is not like the other. *J Neurotrauma*. 2017;34:3070–80. <https://doi.org/10.1089/neu.2017.5129>.
 46. Gomez A, Sainbhi AS, Stein KY, et al. Statistical properties of cerebral near infrared and intracranial pressure-based cerebrovascular reactivity metrics in moderate and severe neural injury: a machine learning and time-series analysis. *ICMx*. 2023;11:57. <https://doi.org/10.1186/s40635-023-00541-3>.
 47. Gomez A, Sekhon M, Griesdale D, et al. Cerebrovascular pressure reactivity and brain tissue oxygen monitoring provide complementary information regarding the lower and upper limits of cerebral blood flow control in traumatic brain injury: a Canadian High Resolution-TBI (CAHR-TBI) cohort study. *Intensive Care Med Exp*. 2022;10:54. <https://doi.org/10.1186/s40635-022-00482-3>.
 48. Gomez A, Griesdale D, Froese L, et al. Temporal statistical relationship between regional cerebral oxygen saturation (rSO₂) and brain tissue oxygen tension (PbtO₂) in moderate-to-severe traumatic brain injury: a Canadian High Resolution-TBI (CAHR-TBI) Cohort Study. *Bioengineering (Basel)*. 2023;10:1124. <https://doi.org/10.3390/bioengineering10101124>.
 49. Plachky J, Hofer S, Volkmann M, et al. Regional cerebral oxygen saturation is a sensitive marker of cerebral hypoperfusion during orthotopic liver transplantation. *Anesth Analg*. 2004;99:344–9. <https://doi.org/10.1213/01.ANE.0000124032.31843.61>.
 50. Yu Y, Zhang K, Zhang L, et al. Cerebral near-infrared spectroscopy (NIRS) for perioperative monitoring of brain oxygenation in children and adults. *Cochrane Database Syst Rev*. 2018;1:CD010947. <https://doi.org/10.1002/14651858.CD010947.pub2>.
 51. Davies DJ, Su Z, Clancy MT, et al. Near-infrared spectroscopy in the monitoring of adult traumatic brain injury: a review. *J Neurotrauma*. 2015;32:933–41. <https://doi.org/10.1089/neu.2014.3748>.
 52. Gomez A, Dian J, Froese L, Zeiler FA. Near-infrared cerebrovascular reactivity for monitoring cerebral autoregulation and predicting outcomes in moderate to severe traumatic brain injury: proposal for a pilot observational study. *JMIR Res Protoc*. 2020;9:e18740. <https://doi.org/10.2196/18740>.
 53. Gomez A, Dian J, Zeiler FA. Continuous and entirely non-invasive method for cerebrovascular reactivity assessment: technique and implications. *J Clin Monit Comput*. 2020. <https://doi.org/10.1007/s10877-020-00472-4>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.